Akèy › Kansè tèt ak kou
Etid klinik pou Kansè tèt ak kou ap rekrite nan Etazini
146 etid pou Kansè tèt ak kou ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX30 etid
- Boston, MA22 etid
- New York City, NY21 etid
- Nashville, TN21 etid
- St. Louis, MO15 etid
- Dallas, TX12 etid
- Pittsburgh, PA11 etid
- Durham, NC10 etid
- San Antonio, TX10 etid
- Los Angeles, CA10 etid
- Chicago, IL10 etid
- Baltimore, MD10 etid
- Miami, FL10 etid
- Washington, DC10 etid
- Edison, NJ9 etid
- Philadelphia, PA9 etid
- Tampa, FL9 etid
- Cleveland, OH9 etid
- San Francisco, CA9 etid
- Rochester, MN8 etid
- Portland, OR8 etid
- Columbus, OH8 etid
- New Haven, CT8 etid
- Charleston, SC8 etid
- San Diego, CA7 etid
- Baldwin Park, CA7 etid
- New Rochelle, NY6 etid
- Queens, NY6 etid
- Staten Island, NY6 etid
- Arlington, VA6 etid
- Aurora, CO6 etid
- Mountain View, CA6 etid
- Orlando, FL6 etid
- Birmingham, AL5 etid
- Sacramento, CA5 etid
- Newark, NJ5 etid
- Memphis, TN5 etid
- Atlanta, GA5 etid
- Cedar Rapids, IA5 etid
- Salt Lake City, UT5 etid
Pa eta
- Alabama5 etid
- Arizona4 etid
- Arkansas3 etid
- Colorado9 etid
- Connecticut10 etid
- Delaware3 etid
- Distrik Columbia5 etid
- Florid24 etid
- Georgia7 etid
- Illinois11 etid
- Iowa5 etid
- Kalifòni31 etid
- Kansas7 etid
- Kentucky5 etid
- Lwizyàn3 etid
- Maryland15 etid
- Massachusetts24 etid
- Michigan10 etid
- Minnesota10 etid
- Missouri16 etid
- Nebraska4 etid
- New Jersey13 etid
- New Mexico3 etid
- New York29 etid
- North Carolina14 etid
- Ohio19 etid
- Oklahoma6 etid
- Oregon8 etid
- Pennsylvania20 etid
- Rhode Island4 etid
- South Carolina10 etid
- Tennessee23 etid
- Texas42 etid
- Utah7 etid
- Virginia12 etid
- Washington5 etid
- Wisconsin8 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06788990The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750Distance-Based Exercise to Preserve Function and Prevent Disability
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07059884[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Oct 2, 2026 · NCT06479811Biospecimen Procurement for Head and Neck Disorders
Ap rekriteEtid obsèvasyon
Laj 3 a 120 · Tout sèks · Mizajou Oct 2, 2026 · NCT03429036A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06172478A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07090499Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06997068A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07085091Online Perioperative Education Program on Patient Satisfaction and Clinical Outcomes for Head and Neck Surgery
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07848841A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07814248NIDCD Otolaryngology Clinical Protocol Biospecimen Bank
Ap rekriteEtid obsèvasyon
Laj 3 a 99 · Tout sèks · Mizajou Sep 28, 2026 · NCT06303180DESTINY-PANTUMOUR04
Ap rekriteEtid obsèvasyon
Laj 18 a 130 · Tout sèks · Mizajou Sep 25, 2026 · NCT07124000Pilot Study of Management of Facial Paralysis in the Oncologic Patient: Nerve Transfer Techniques to Improve Facial Function and Quality of Life
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06667427Intratumoral N17350 in Advanced Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07339176Continuous Monitoring of Microvascular Anastomoses: An Observational Trial
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07823283Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT06736379A Pilot Study of Ultra-High Dose Rate (ConformalFLASH®), for Reirradiation of Carcinoma of the Head and Neck
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07644585Postoperative Radiotherapy for Intermediate- and High-risk Patients With HNSCC Greater Than 6 Weeks After Surgery
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT06607406A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07020117Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT06096038Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06633224Effects of Infusion Timing on Treatment Response in Solid Tumors
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07630168Exercise and Nutritional Prehabilitation for Head and Neck Cancer Patients
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06722508First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06657222Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.